HOT1303-B trial was a multicenter, single-arm phase II study of trastuzumab for pretreated HER2-altered NSCLC patients, which were defined as HER2 mutations, IHC 3+ or IHC 2+/dual color in situ hybridization [DISH]+. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.